Licensing
Innova Biosciences and Cancer Research Technology (CRT), the commercialisation arm of Cancer Research UK, have signed a licence agreement to develop a portfolio of conjugated antibodies against novel oncology targets.
Innova specialises in bioconjugation, the joining of two molecules to form hybrid conjugates, for use in diagnostic tests. Innova has developed a one-step conjugation method, Lightning-Link, which is much faster and easier to perform than existing techniques
Under the deal, Innova will generate a collection of novel antibody research tools for the research community. Cancer Research UK funds 4,500 researchers in the UK.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.